Healthcare [ 13/13 ] | Biotechnology [ 105/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 9, 23 | -0.11 Decreased by -132.35% | -1.1 Increased by +90% |
| Aug 3, 23 | -0.59 Increased by +57.25% | -0.8 Increased by +26.25% |
| May 4, 23 | -0.85 Increased by +64.58% | -0.97 Increased by +12.37% |
| Mar 29, 23 | -1.04 Increased by +45.83% | -0.73 Decreased by -42.47% |
| Nov 7, 22 | 0.34 Increased by +116.67% | -1.09 Increased by +131.19% |
| Aug 4, 22 | -1.38 Increased by +36.11% | -1.77 Increased by +22.03% |
| May 5, 22 | -2.4 Increased by +37.5% | -1.6 Decreased by -50% |
| Mar 2, 22 | -1.92 Increased by +11.11% | -1.9 Decreased by -1.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 236 K Decreased by -98.42% | -5.23 M Decreased by -263.78% | Decreased by -2.22 K% Decreased by -10.47 K% |
| Jun 30, 23 | 643 K Decreased by -37.75% | -8.19 M Increased by +36.91% | Decreased by -1.27 K% Decreased by -1.35% |
| Mar 31, 23 | 475 K Decreased by -59.51% | -9.96 M Increased by +54.85% | Decreased by -2.1 K% Decreased by -11.49% |
| Dec 31, 22 | 896 K Increased by +309.13% | -9.81 M Increased by +48.89% | Decreased by -1.1 K% Increased by +87.51% |
| Sep 30, 22 | 14.95 M Increased by +1.01 K% | 3.19 M Increased by +118.35% | Increased by +21.35% Increased by +101.66% |
| Jun 30, 22 | 1.03 M Decreased by -69.21% | -12.99 M Increased by +24.07% | Decreased by -1.26 K% Decreased by -146.59% |
| Mar 31, 22 | 1.17 M Increased by +147.99% | -22.05 M Increased by +28.13% | Decreased by -1.88 K% Increased by +71.02% |
| Dec 31, 21 | 219 K Decreased by -85.36% | -19.2 M Decreased by -22.72% | Decreased by -8.77 K% Decreased by -738.38% |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.